The U.S. Food and Drug Administration (FDA) said that Johnson & Johnson’s single-dose vaccine prevents COVID-19 and will make a final decision soon. The company carried out a study of 44,000 patients in South Africa, the United States, and several other countries, according to the agency, adding that there were seven COVID-19 deaths among patients receiving a placebo—and none who got the vaccine. “There were no specific safety concerns identified in subgroup analyses by age, race, ethnicity, medical comorbidities, or prior SARS-CoV-2 infection,” the analysis said. The J&J vaccine against the moderate to severe CCP virus cases was 66.9 percent at least 14 days after the single-dose vaccination and 66.1 percent at least 28 days after the shot was administered, according to the FDA, as reported by CNN and other news outlets. The vaccine was 72 percent effective in the U.S. alone, said J&J. It, however, said the vaccine was only 57 …